Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial

Fosså, Alexander ; Molin, Daniel ; Bröckelmann, Paul J. ; Schneider, Gundolf ; Schnetzke, Ulf ; Linderoth, Johan LU ; Kamper, Peter M.H. ; Leppä, Sirpa M. ; Meissner, Julia and Schaub, Valdete , et al. (2025) In HemaSphere 9(3).
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
HemaSphere
volume
9
issue
3
article number
e70099
publisher
Wolters Kluwer
external identifiers
  • scopus:105000545482
  • pmid:40124718
ISSN
2572-9241
DOI
10.1002/hem3.70099
language
English
LU publication?
yes
id
ed99af31-1cd7-4821-8ea5-b3a579eabeb8
date added to LUP
2025-08-26 11:08:10
date last changed
2025-08-27 03:00:08
@article{ed99af31-1cd7-4821-8ea5-b3a579eabeb8,
  author       = {{Fosså, Alexander and Molin, Daniel and Bröckelmann, Paul J. and Schneider, Gundolf and Schnetzke, Ulf and Linderoth, Johan and Kamper, Peter M.H. and Leppä, Sirpa M. and Meissner, Julia and Schaub, Valdete and Lia, Kjersti and Fuchs, Michael and Borchmann, Peter and Böll, Boris}},
  issn         = {{2572-9241}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Wolters Kluwer}},
  series       = {{HemaSphere}},
  title        = {{Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial}},
  url          = {{http://dx.doi.org/10.1002/hem3.70099}},
  doi          = {{10.1002/hem3.70099}},
  volume       = {{9}},
  year         = {{2025}},
}